Neomycin

Colorectal Cancer

M.D. Anderson Cancer CentermixturePhase 4 / ApprovedActive

B

58/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 57/ 100
Competitive Position: 59/ 100

Competitive context

713 Active assets in the Colorectal Cancer cohort.

Asset / Sponsor	Phase	Rating
Desflurane Peter MacCallum Cancer Centre, Australia	Phase 4	BBB
Marble Dust James Varani	Phase 2/3	BB
Orectalip Sinphar Pharmaceutical Co., Ltd	Phase 4	BB
Fluorouracilum UNICANCER	Phase 4	BB
Levofolinic Acid Suzhou Suncadia Biopharmaceuticals Co., Ltd.	Phase 3	BB

View all 50 →

Same molecule, other indications

Neomycin is also rated in:

rectal carcinomaActive

B

Indicative · Phase 4

63 / 100

colorectal neoplasmActive

B

Indicative · Phase 4

63 / 100

post-operative gastrointestinal anastomotic dehiscence, non-human animalDormant

CCC

Indicative · Phase 2

53 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.